Bridgebio Oncology Therapeutics Inc (BBOT)

Feb 12, 2026

BBOT to Participate in Upcoming Investor Healthcare Conferences - Bitget

Feb 12, 2026

Feb 11, 2026

Stifel Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Buy Recommendation - Nasdaq

Feb 11, 2026

Feb 11, 2026

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 11, 2026

Feb 11, 2026

This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga

Feb 11, 2026

Feb 11, 2026

Stifel Nicolaus Initiates Coverage on BridgeBio Oncology Therapeutics With Buy Rating, $23 Price Target - marketscreener.com

Feb 11, 2026

Feb 10, 2026

Stifel initiates coverage on BridgeBio Oncology stock with Buy rating By Investing.com - Investing.com India

Feb 10, 2026

Feb 10, 2026

Stifel initiates coverage on BridgeBio Oncology stock with Buy rating - Investing.com

Feb 10, 2026

Feb 08, 2026

Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO), Bristol-Myers Squibb (BMY) and Qiagen (QGEN) - The Globe and Mail

Feb 08, 2026

Jan 30, 2026

Finance Watch: SPACs Attempt A Comeback As IPO Market Shows Signs Of Life - Citeline News & Insights

Jan 30, 2026

Jan 26, 2026

Biotech investor Cormorant secures $150M for another SPAC deal - BioPharma Dive

Jan 26, 2026

Jan 25, 2026

A Look At BridgeBio Oncology Therapeutics (BBOT) Valuation After Recent Share Price Momentum - Yahoo Finance

Jan 25, 2026

Jan 20, 2026

Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results - Finviz

Jan 20, 2026

Jan 12, 2026

BBOT: Robust efficacy and safety data position these assets as leaders in KRAS-targeted cancer therapy - TradingView — Track All Markets

Jan 12, 2026

Jan 09, 2026

Raymond James Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Outperform Recommendation - Nasdaq

Jan 09, 2026

Jan 09, 2026

BridgeBio Oncology stock initiated with Outperform rating at Raymond James By Investing.com - Investing.com Nigeria

Jan 09, 2026

Jan 09, 2026

Raymond James Initiates BridgeBio Oncology Therapeutics at Outperform With $24 Price Target - marketscreener.com

Jan 09, 2026

Jan 09, 2026

BridgeBio Oncology stock initiated with Outperform rating at Raymond James - Investing.com

Jan 09, 2026

Jan 08, 2026

BridgeBio Oncology stock price target raised to $32 from $25 at Leerink - Investing.com Canada

Jan 08, 2026

Jan 07, 2026

BridgeBio Oncology stock maintains Overweight rating at Morgan Stanley By Investing.com - Investing.com Nigeria

Jan 07, 2026

Jan 07, 2026

Oppenheimer reiterates Outperform rating on BridgeBio Oncology stock By Investing.com - Investing.com Canada

Jan 07, 2026

Jan 07, 2026

BridgeBio Oncology stock maintains Overweight rating at Morgan Stanley - Investing.com

Jan 07, 2026

Jan 07, 2026

BBOT: Promising efficacy and safety for three RAS-pathway inhibitors, with key data expected in 2026 - TradingView — Track All Markets

Jan 07, 2026

Jan 07, 2026

BridgeBio Oncology reports positive data from RAS-pathway cancer trials - Investing.com

Jan 07, 2026

Jan 07, 2026

BridgeBio Oncology reports positive data from RAS-pathway cancer trials By Investing.com - Investing.com Nigeria

Jan 07, 2026

Jan 07, 2026

BridgeBio Oncology Therapeutics, Inc. Announces New Clinical Data for RAS and PI3Kα Programs - TradingView — Track All Markets

Jan 07, 2026

Jan 07, 2026

BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs - The Manila Times

Jan 07, 2026

Jan 02, 2026

BridgeBio Oncology Therapeutics, Inc.Common Stock (NQ: BBOT - FinancialContent

Jan 02, 2026

Dec 21, 2025

BridgeBio Oncology Therapeutics, Inc.(NasdaqGM: BBOT) added to S&P Global BMI Index - marketscreener.com

Dec 21, 2025

Dec 19, 2025

BridgeBio Oncology Therapeutics Earnings Notes - Trefis

Dec 19, 2025

Dec 16, 2025

BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times

Dec 16, 2025

Dec 15, 2025

Assessing BridgeBio Oncology Therapeutics (BBOT) Valuation After Recent Share Price Pullback - Yahoo Finance

Dec 15, 2025

Dec 15, 2025

Wedbush Reiterates BridgeBio Oncology Therapeutics (BBOT) Outperform Recommendation - MSN

Dec 15, 2025

Dec 12, 2025

BridgeBio Oncology Therapeutics (BBOT) updates CEO option grant terms - Stock Titan

Dec 12, 2025

Dec 12, 2025

BridgeBio Oncology Therapeutics: Promising KRAS Drug DeveloperIn My View, At Least - Seeking Alpha

Dec 12, 2025

Dec 11, 2025

BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 11, 2025

Dec 11, 2025

Wedbush Reiterates Outperform Rating for BBOT; Price Target Unch - GuruFocus

Dec 11, 2025

Dec 11, 2025

BridgeBio Oncology initiated with an overweight at Morgan Stanley - MSN

Dec 11, 2025

Dec 10, 2025

BridgeBio Oncology (BBOT) Stock Analysis Report | Financials & Insights - Benzinga

Dec 10, 2025

Dec 10, 2025

BridgeBio Oncology Therapeutics, Inc. Announces Late-Breaking Preclinical Data on BBO-10203, a First-In-Class RAS:PI3Ka Breaker, at the San Antonio Breast Cancer Symposium - marketscreener.com

Dec 10, 2025

Dec 10, 2025

BBOT Announces Late-Breaking Preclinical Data on BBO-10203, - GlobeNewswire

Dec 10, 2025

Dec 08, 2025

BridgeBio Oncology stock reaches all-time high at 14.87 USD By Investing.com - Investing.com Canada

Dec 08, 2025

Dec 08, 2025

BridgeBio Oncology stock reaches all-time high at 14.87 USD - Investing.com India

Dec 08, 2025